By Fineline Cube 
China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic collaboration with Shanghai Pharmaceuticals Holding Co., Ltd (HKG: 2607, SHA: 601607; SPH). This partnership grants Shanghai Pharma exclusive omni-channel terminal promotion and national distribution rights for Boan’s BA5101 in mainland China.
About BA5101
BA5101 is a biosimilar of Eli Lilly’s Trulicity (dulaglutide), designed for blood glucose control in adults with type 2 diabetes. It is currently under marketing review in China and has been approved for clinical trials in the United States. As the world’s first Trulicity biosimilar to file for marketing, BA5101 demonstrates high consistency with the originator in quality, safety, and immunogenicity.
Trulicity Mechanism and Benefits
Trulicity, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, activates GLP-1 receptors to increase cyclic adenosine monophosphate (cAMP) in β cells. This action causes glucose-dependent insulin release, inhibits glucagon secretion, and delays gastric emptying. Its unique mechanism reduces the risk of hypoglycemia and offers benefits such as weight reduction, improved blood lipids, and a protective effect on the kidneys. The weekly administration schedule enhances patient convenience, reduces gastrointestinal side effects, and improves compliance.-Fineline Info & Tech